Breaking News

Takeda, Wipro Enter Global IT Platform Pact

May 20, 2014

Wipro to build and maintain an "as-a-service" global platform

Wipro Ltd. has entered a strategic partnership with Takeda Pharmaceutical Co. to consolidate its IT platforms across the organization. Wipro will be the primary provider of IT Infrastructure management services and will build and maintain an "as-a-service" global platform for Takeda aimed at driving synergies across its global entities through standardization of IT architecture.

Sangita Singh, chief executive officer of Healthcare and Life Science Business Unit at Wipro said, "We are thrilled to partner with Takeda in its business transformation journey. Wipro is leveraging its experience in enabling global pharma companies to achieve a leaner & standardized IT workplace and implement newer business models that put patient at the core. We look forward to collaboratively partnering with the Takeda team in enabling this unique platform across its global operations."
 
"Wipro will deliver the 'as-a-service' on demand model, which is redefining the way organizations purchase technology. With our global delivery capabilities, Wipro will drive Takeda's IT infrastructure, consolidating and optimizing resources across the organization," added G K Prasanna, chief executive officer of Global Infrastructure Services & Product Engineering Services.
blog comments powered by Disqus
  • Packaging Equipment Close-Up

    Packaging Equipment Close-Up

    Kristin Brooks, Contract Pharma||March 9, 2016
    To meet the wide-ranging needs of the marketplace, suppliers and contract packagers are looking to deliver flexible solutions.

  • Top 25 Pharma and Biopharma Report

    Top 25 Pharma and Biopharma Report

    July 20, 2015
    (Based on 2014 Sales, in $U.S. Millions)

  • Driving Innovation Through Contracting

    Driving Innovation Through Contracting

    David Agrella, Bryan Haas, Pharm.D., Timothy King, Dr.P.H. and Scott Maisto , PPD||November 13, 2014
    This article discusses the advantages to both biopharmaceutical companies and their vendors of moving outsourcing spend to a commercial model focused on the desired deliverable and not the level of effort required to achieve the deliverable.